Author + information
- Mithun Devraj,
- Amit Dey,
- Heather Teague,
- Justin Rodante,
- Raja Zaghlol,
- Andrew Keel,
- Aditya A. Joshi,
- Marcus Y. Chen,
- Martin Playford and
- Nehal Mehta
Psoriasis is a systemic inflammatory disease associated with increased cardiovascular risk and impaired cholesterol efflux. Cholesterol efflux capacity (CEC), the ability of HDL to accept cholesterol from macrophages has been shown to be associated with noncalcified coronary burden (NCB) in psoriasis. Apolipoprotein A1 (apo A1) levels have been shown to predict coronary artery disease (CAD) better than HDL. We evaluated whether apoA1 can be used as a surrogate for CEC in its relationship with NCB.
NCB was assessed in 288 consecutive psoriasis patients by coronary computed tomography angiography using quantitative imaging software (QAngio, Medis). CEC was quantified using a cell-based ex vivo assay measuring the ability of apo B depleted plasma to mobilize cholesterol from lipid-loaded macrophages. ApoA1 levels were measured using mass spectrometry.
Psoriasis patients were middle aged, predominantly male, low cardiovascular risk by Framingham risk score and had moderate-severe psoriasis severity. Apo A1 levels positively associated with CEC (Beta= 0.53, p <0.001) (Figure 1A). Furthermore, Apo A1 levels negatively associated with NCB (Beta = – 0.29, p <0.001) (Figure 1B) and this relationship persisted even when adjusted for CEC (Beta = – 0.25, p <0.001).
Apo A1 levels positively associated CEC in psoriasis. Moreover, ApoA1 associated with NCB even on adjustment for CEC, suggesting that apoA1 may be used as a surrogate for CEC to capture CAD risk in psoriasis.
Posters Hall_Hall A
Sunday, March 29, 2020, 3:45 p.m.-4:30 p.m.
Session Title: Prevention: Clinical 6
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1360-122
- 2020 American College of Cardiology Foundation